摘要
目的 :探讨临床感染性标本中大肠埃希菌产超广谱 β -内酰胺酶 (ESBL)的情况及耐药状况 ,以指导临床合理用药。方法 :采用浓度梯度法 (E -test法 )和Vitek微生物自动分析仪进行ESBL的检测 ,采用K -B法对临床感染标本中分离出的 12 0株大肠埃希菌进行药敏试验。结果 :12 0株大肠埃希菌对亚胺培南耐药最低 ,耐药率为 5 % ;其次为头孢哌酮 /舒巴坦耐药率为 5 .8% ;对丁胺卡那和头孢他啶也显示较低的耐药性 ,分别为 8.3 %和 15 .8%。 12 0株大肠埃希菌产超广谱 β -内酰胺酶为 18.3 3 %。 结论 :产超广谱 β-内酰胺酶的大肠埃希菌对广谱头孢菌素及氨曲南耐药 ,耐药性明显高于非产酶株。亚胺培南和头孢派酮 /舒巴坦可作为ESBL阳性菌株感染治疗的首选药物。
Objective: To study the producing ratese of extended-spectrum beta-lactamase (ESBL) and resistance to antibiotics among Escherichia coli(E.coli) islated from clinical infective specimen. To indicate clincal infective specimen. To indicate clincal selecting rationaly usage of drugs. Methods: susceptibility to antibiotics'tests of 120 E.coli strains was measured by K-B paper disk diffusion. ESBL'detection was measured by concentration gradient method of E-test and VITEK microbe auto-analysis instrument respectively. Results: the drug-resistant rates among 120 E.coli strains to Imipenem were lowest with 5%. The drug-resistant rates of E.coli to Cefoperazone Sulbactam、Amikacin and Ceftazidime were, respectively, 5.8%、8.3%、15.8%. The rates of producing ESBL among 120 E.coli strains were 18.33%.Conclusion: ESBL-producing E.coli is resistant to Cephalosporin and Aztreonam, and it's resistance is higher than non-ESBL-producing E.coli markedly.Imipenem and Cefoperazone Sulbactam are the first-choice drugs for treating ESBL-producing E.coli infection.
出处
《航空航天医药》
2003年第3期140-142,共3页
Aerospace Medicine
关键词
大肠埃希菌
超广谱Β-内酰胺酶
耐药性
Escherichia
coli Extended-wpectrum beta-lactamase
Drug-resistance
